On October 30, 2025 Jecho Laboratories, Inc. reported it will present emerging clinical data from a Phase 1 study of JL18008, an innovative IL-7/HSA fusion protein for HIV immunological non-responders and lymphocytopenia, at the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) 40th Annual Meeting.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The SITC (Free SITC Whitepaper) meeting will be held November 5 – 9, 2025 in National Harbor, Maryland.

Details on the presentation are below:

Abstract 1339: A randomized, double-blind, placebo-controlled, dose-escalated, first-in-human study to assess the safety, tolerability, and T cell replenishment of JL18008, a long-acting IL-7, in healthy subjects

Abstract Presentation Number: 1339
Session Time: Friday, November 7, 2025 viewing 10 a.m. – 7 p.m. EST
Location: Gaylord National Resort & Convention Center – Exhibit Halls AB

(Press release, Jecho Laboratories, OCT 30, 2025, View Source [SID1234657154])